Understanding human gene function in living organisms has long been hampered by fundamental differences between species.
REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative ...
Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...
If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...
True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...
On Dec. 16, 2025, Northwell’s Cohen Children’s Medical Center became the first hospital in New York State to administer Casgevy® to a patient — a life-changing genetic therapy for sickle cell disease.
PHILADELPHIA and LONDON, Dec. 18, 2025 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing ...
Lauren Pastrana is the co-anchor of CBS4 News weeknights at 5, 6, 7 and 11 p.m. She joined CBS Miami in April 2012 as a reporter. She is an Emmy-nominated, multimedia journalist with experience in ...
Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute lymphoblastic leukemia (T-ALL). This form of therapy used genome editing ...
Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group specializing in the development and manufacturing of cell culture media, has launched CELLiSTTM AAV Production Supplement 1, a newly ...
Aradigm Health, a new benefits platform aimed at easing the financial sting of coverage for cell and gene therapies, has launched out of stealth. The company is making its debut backed by a $20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback